Heron Therapeutics, Inc.

Contributing Author

Recent Articles by Heron Therapeutics, Inc.

Apr-27	Heron Therapeutics to Report First Quarter 2026 Financial Results on Monday, May 11, 2026 HRTX GlobeNewswire
Feb-26	Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results HRTX +11.11% GlobeNewswire
Feb-17	Heron Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026 HRTX GlobeNewswire
Jan-09	Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF Largest Contributor to Q4 Growth HRTX +9.45% GlobeNewswire
Dec-04	Heron Therapeutics Announces Inclusion of APONVIE (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV) HRTX GlobeNewswire
Nov-04	Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress HRTX GlobeNewswire
Oct-29	Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors HRTX GlobeNewswire
Oct-21	Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 HRTX -8.46% HRTX GlobeNewswire